et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J. Clin. Oncol. 23, 17–23 (2005). Article CAS PubMed Google Scholar Pierce, L. J. et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in...
Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.
55 The need for encouraging these interventions for women with coronary disease is illustrated by the facts that 90% of the HERS cohort had LDL cholesterol exceeding 2.59 mmol/L (100 mg/dL) at baseline and that only 32% were receiving β-blockers. Conclusions First, in the population ...
I’ve just been diagnosed with stage 1 breast cancer. Thanking the Lord it was found early. The cancer is estrogen dominate. I saw a naturalpath and she put me on DIM because I wanted to do everything I can, naturally, to lower the estrogen in my body. Interesting that high estrogen ...
Estrogen Receptor-α (ERα) expression is increased in prostate cancer and acts as an oncogene. We propose that blocking of estrogen hormone binding to ERα using the ERα blocker toremifene will reduce the tumorigenicity of prostate cancer, and nano-targeted delivery of ...
Western blots of total ERK1/2 demonstrated that the total amount of this MAPK was unchanged after treatment of female growth zone cells for either 9 or 90 min (Fig. 2B). However, phosphorylated ERK1/2 was increased and peak levels were seen in cells treated with 10− 9 M for 9 min...
This is in agreement with our previous finding in breast epithelial cells [16]. To identify the source of intracellular ROS, we tried to suppress E2 triggered ROS production using selective chemical blockers. In HUVECs that were co-treated with the mitochondrial complex I inhibitor rotenone, we...
betablockerstresshumanp pBackground/p pSelective estrogen receptor modulators (SERMs) have been developed in order to create means to control estrogenic effects on different tissues. A major drawback in treatment of estrogen receptor (ER) positive breast cancer with the antagonist tamoxifen (TAM) ...
Article CAS PubMed PubMed Central Google Scholar Antoniou, A.C. et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population. Nat. Genet. 42, 885–892 (2010). Article CAS Pub...
Mechanisms of endocrine resistance in breast cancer. Ann Rev Med 2011; 62: 233–247. Article CAS Google Scholar Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN . Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1–22. Article ...